Development of a new Cox-2 inhibitor as an anticancer agent

  • Park, Jeong-Ran (Catholic Res Inst of Med Sci, Catholic Univ of Korea) ;
  • Hyoung, Kang-Jin (Catholic Res Inst of Med Sci, Catholic Univ of Korea) ;
  • Young, Noh-Ji (Inst of Science & Technology, Cheil Jedang Corporation) ;
  • Chul, Ryu-Hyung (Inst of Science & Technology, Cheil Jedang Corporation) ;
  • Park, Sang-Wook (Inst of Science & Technology, Cheil Jedang Corporation) ;
  • Hwan, Cho-Il (Inst of Science & Technology, Cheil Jedang Corporation) ;
  • H, Hwang-Daniel (Pennington Biomedical Res Center, Louisiana State Univ.) ;
  • Kim, In-Kyung (Catholic Res Inst of Med Sci, Catholic Univ of Korea) ;
  • Jeog, Kuh-Hyo (Catholic Res Inst of Med Sci, Catholic Univ of Korea)
  • Published : 2002.10.01

Abstract

Cyclooxygenase (Cox-2) is involved in tumorigenesis. hence. considered to be a molecular target for chemoprevention and chemomodulation. Selective Cox-2 inhibitors including Celecoxib and Nimesulide have been studied for their anticancer activity when given alone and in combination with radiation or cytotoxic agents. In this study, we synthesized more than 140 analogues of Celecoxib and Nimesulide. and evaluated their inhibitory effects on Cox-l and Cox-2 activity as well as cytotoxicity in order to find promising anticancer agents having selective Cox-2 inhibitory effect. (omitted)

Keywords